The United States Food and Drug Administration (FDA) has approved a cross-linked hyaluronic acid dermal filler from Ontario, Canada-based Prollenium Medical Technologies. The soft tissue filler is sold under the brand Revanesse in Canada. At the time of print, Prollenium had not announced a brand name or date of commercial availability in the U.S.
In reference to the recent approval, the company’s founder and CEO Ario Khoshbin stated: “This is definitely one of our proudest moments as an organization. FDA approval is a culmination of efforts from every single member of our team. As an organization, we have been working towards this goal from the first day the company opened its doors, and to see it come to fruition is a validation of our vision. The U.S. market and its potential will be an exciting challenge for our team, but one that will have many rewards for our business both in the U.S. and globally.”
Image copyright Getty Images
